Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LNG035
MIFTS: 54

Lung Large Cell Carcinoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lung Large Cell Carcinoma

About this section

MalaCards integrated aliases for Lung Large Cell Carcinoma:

Name: Lung Large Cell Carcinoma 12 15
Large Cell Carcinoma of Lung 12 71
Large Cell Lung Carcinoma 12 17
Large Cell Lung Cancer 54

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Respiratory diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4556
NCIt 50 C4450
SNOMED-CT 67 254629004
UMLS 71 C0345958
Sources

Summaries for Lung Large Cell Carcinoma

About this section
MalaCards based summary : Lung Large Cell Carcinoma, also known as large cell carcinoma of lung, is related to large cell neuroendocrine carcinoma and lung squamous cell carcinoma. An important gene associated with Lung Large Cell Carcinoma is ROS1 (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and thyroid, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Large-cell carcinoma (LCC) is a heterogeneous group of undifferentiated malignant neoplasms that lack... more...

Sources

Related Diseases for Lung Large Cell Carcinoma

About this section

Diseases in the Lung Large Cell Carcinoma family:

Small Cell Cancer of the Lung Lung Clear Cell Carcinoma

Diseases related to Lung Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 192)
# Related Disease Score Top Affiliating Genes
1 large cell neuroendocrine carcinoma 30.9 SYP NTRK3 NKX2-1 NCAM1 CHGA
2 lung squamous cell carcinoma 30.3 TTN ROS1 FGFR1 DDR2
3 adenocarcinoma 29.7 ROS1 NTRK3 NKX2-1 FGFR1 EPHA5 EPHA3
4 neuroendocrine carcinoma 29.3 SYP NKX2-1 NCAM1 CHGA
5 small cell carcinoma 29.3 SYP NKX2-1 NCAM1 CHGA
6 large cell carcinoma 29.1 SYP ROS1 NKX2-1 NCAM1 MTOR FGFR1
7 lung cancer 29.0 SYP ROS1 NME1 NKX2-1 NCAM1 MYO18B
8 lung mixed small cell and squamous cell carcinoma 11.3
9 lung giant cell carcinoma 11.2
10 malignant giant cell tumor of the tendon sheath 10.4 ROS1 NTRK3
11 myeloid and lymphoid neoplasms associated with pdgfra rearrangement 10.4 FGFR1 ABL1
12 perinephritis 10.3 TTN ROS1
13 rosette-forming glioneuronal tumor 10.3 SYP FGFR1
14 spinal cord oligodendroglioma 10.2 SYP FGFR1
15 mucinous lung adenocarcinoma 10.2 ROS1 NKX2-1
16 thrombocytosis 10.2
17 giant cell glioblastoma 10.2 SYP MTOR FGFR1
18 primary hepatic neuroendocrine carcinoma 10.2 SYP CHGA
19 auditory system benign neoplasm 10.1 SYP CHGA
20 auditory system cancer 10.1 SYP CHGA
21 acinar cell cystadenocarcinoma 10.1 SYP CHGA
22 vulvar eccrine porocarcinoma 10.1 SYP CHGA
23 cauda equina neoplasm 10.1 SYP CHGA
24 gastrointestinal neuroendocrine benign tumor 10.1 SYP CHGA
25 thymus clear cell carcinoma 10.1 TTN NKX2-1
26 ampulla of vater neoplasm 10.1 SYP CHGA
27 appendix carcinoid tumor 10.1 SYP CHGA
28 vaginal tubulovillous adenoma 10.1 SYP CHGA
29 mixed ductal-endocrine carcinoma 10.1 SYP CHGA
30 middle ear adenoma 10.1 SYP CHGA
31 duodenal benign neoplasm 10.1 SYP CHGA
32 breast papillary carcinoma 10.1 SYP CHGA
33 gastric neuroendocrine neoplasm 10.1 SYP CHGA
34 appendix adenocarcinoma 10.1 SYP CHGA
35 gastric hemangioma 10.1 SYP CHGA
36 thymus basaloid carcinoma 10.1 SYP NKX2-1
37 lung meningioma 10.1 SYP NKX2-1
38 pineocytoma 10.1 SYP CHGA
39 pancreatic gastrinoma 10.1 SYP CHGA
40 cervix small cell carcinoma 10.1 SYP CHGA
41 adrenal neuroblastoma 10.1 SYP CHGA
42 adenosquamous carcinoma 10.1
43 vasculitis 10.1
44 squamous cell carcinoma 10.1
45 cerebrofacial arteriovenous metameric syndrome 10.1
46 gastrointestinal neuroendocrine tumor 10.1 SYP MTOR CHGA
47 ureteral benign neoplasm 10.1 SYP NKX2-1
48 vaginal adenoma 10.1 SYP CHGA
49 anal neuroendocrine tumor 10.1 SYP NCAM1
50 vaginal benign neoplasm 10.1 SYP CHGA

Graphical network of the top 20 diseases related to Lung Large Cell Carcinoma:



Diseases related to Lung Large Cell Carcinoma
Sources

Symptoms & Phenotypes for Lung Large Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.85 MTOR EPHA3
2 Decreased viability GR00055-A-2 10.85 MTOR EPHA3
3 Decreased viability GR00055-A-3 10.85 EPHA3
4 Decreased viability GR00173-A 10.85 ANKK1
5 Decreased viability GR00221-A-1 10.85 ABL1 DDR2 FGFR1 MTOR NME1 ROS1
6 Decreased viability GR00221-A-2 10.85 ABL1 DDR2 FGFR1 NME1 ROS1 STK33
7 Decreased viability GR00221-A-3 10.85 ABL1 EPHA5
8 Decreased viability GR00221-A-4 10.85 DDR2 MTOR STK33 ANKK1 EPHA3 EPHA5
9 Decreased viability GR00249-S 10.85 NME1 ROS1 EPHA3
10 Decreased viability GR00301-A 10.85 EPHA3
11 Decreased viability GR00342-S-1 10.85 ABL1 MTOR ROS1 EPHA3 TTN
12 Decreased viability GR00342-S-2 10.85 ABL1 MTOR
13 Decreased viability GR00342-S-3 10.85 ABL1 TTN
14 Decreased viability GR00386-A-1 10.85 FGFR1
15 Decreased viability GR00402-S-2 10.85 DDR2 NME1
16 Decreased cell migration GR00055-A-1 10.03 ABL1 ALPK3
17 Decreased cell migration GR00055-A-2 10.03 NCAM1
18 Decreased cell migration GR00055-A-3 10.03 MTOR NCAM1
19 Decreased substrate adherent cell growth GR00193-A-1 10 ROS1
20 Decreased substrate adherent cell growth GR00193-A-2 10 ABL1 ALPK3 EPHA3 MTOR ROS1
21 Decreased substrate adherent cell growth GR00193-A-4 10 ABL1 ANKK1 FGFR1
22 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.62 EPHA3 FGFR1 MTOR TTN
23 Decreased cell viability after pRB stimulation GR00230-A-1 9.58 ANKK1 DDR2 STK33
24 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.54 DDR2 EPHA3 STK33
25 Increased colony dispersion (increased number of colonies and decreased number of cells per colony) GR00212-A 9.13 FGFR1 MTOR ROS1
26 Increased viability GR00386-A-1 8.32 ABL1

MGI Mouse Phenotypes related to Lung Large Cell Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.07 ABL1 ALPK3 CHGA DDR2 EPHA3 FGFR1
2 cardiovascular system MP:0005385 10.06 ABL1 ALPK3 CHGA DDR2 EPHA3 FGFR1
3 muscle MP:0005369 9.76 ABL1 ALPK3 CHGA DDR2 FGFR1 MTOR
4 nervous system MP:0003631 9.73 ABL1 ALPK3 CHGA DDR2 EPHA5 FGFR1
5 no phenotypic analysis MP:0003012 9.17 CHGA DDR2 FGFR1 MTOR NKX2-1 NTRK3
Sources

Drugs & Therapeutics for Lung Large Cell Carcinoma

About this section

Drugs for Lung Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
2
Carboplatin Approved Phase 4 41575-94-4 10339178 498142 38904
3
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
4 Immunosuppressive Agents Phase 4
5 Immunologic Factors Phase 4
6 Antimitotic Agents Phase 4
7 Tubulin Modulators Phase 4
8 Albumin-Bound Paclitaxel Phase 4
9
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
10
Vinblastine Approved Phase 3 865-21-4 13342 241903
11
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
12
Etoposide Approved Phase 3 33419-42-0 36462
13
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
14
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
15
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
16
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
17
Lenograstim Approved, Investigational Phase 3 135968-09-1
18
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
19
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21
Tirapazamine Investigational Phase 3 27314-97-2
22 Protein Kinase Inhibitors Phase 3
23
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
24 Etoposide phosphate Phase 3
25 Hematinics Phase 3
26 Epoetin alfa Phase 3 113427-24-0
27 Mitogens Phase 3
28 Immunoglobulins Phase 3
29 Antibodies Phase 3
30 Immunoglobulins, Intravenous Phase 3
31 Antibodies, Monoclonal Phase 3
32 Immunoglobulin G Phase 3
33 Endothelial Growth Factors Phase 3
34 Angiogenesis Inhibitors Phase 3
35 Vitamin B Complex Phase 3
36 Folic Acid Antagonists Phase 3
37 Vitamin B9 Phase 3
38 Folate Phase 3
39 Anti-Bacterial Agents Phase 3
40 Antirheumatic Agents Phase 3
41 Anti-Inflammatory Agents Phase 3
42 Cyclooxygenase Inhibitors Phase 3
43 Cyclooxygenase 2 Inhibitors Phase 3
44 Analgesics, Non-Narcotic Phase 3
45 Analgesics Phase 3
46 Anti-Inflammatory Agents, Non-Steroidal Phase 3
47
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
48
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
49
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
50
Darbepoetin alfa Approved, Investigational Phase 2 209810-58-2, 11096-26-7

Interventional clinical trials:

(show top 50) (show all 116)
# Name Status NCT ID Phase Drugs
1 A Multi-centric, Open-label, Phase II Study Investigating the Combination of Afinitor With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced (Stage IV) Large Cell Lung Cancer With Neuroendocrine Differentiation (LC-NEC) Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
2 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
3 Single-Agent Versus Combination Chemotherapy in Advanced NSCLC: A CALGB Randomized Trial of Efficacy, Quality of Life, and Cost-Effectiveness Completed NCT00003117 Phase 3 carboplatin;paclitaxel
4 A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
5 A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
6 Randomized Phase III Trial Of Carboplatin And Paclitaxel Plus Tirapazamine Versus Carboplatin And Paclitaxel In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
7 RANDOMIZED TRIAL OF SURGERY VERSUS RADIOTHERAPY IN PATIENTS WITH STAGE IIIa NON-SMALL CELL LUNG CANCER AFTER A RESPONSE TO INDUCTION-CHEMOTHERAPY Completed NCT00002623 Phase 3 carboplatin;cisplatin
8 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
9 A Prospective Study of the Prognostic Significance of Occult Metastases in the Patient With Resectable Non-Small Cell Lung Carcinoma Completed NCT00003901 Phase 3
10 A Phase III Trial of Single Versus Fractionated Thoracic Radiation for Palliation of Symptoms in Patients With Non-Small Cell Lung Cancer Completed NCT00003685 Phase 3
11 Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient With N0 and N1 (Less Than Hilar) Non-Small Cell Carcinoma Completed NCT00003831 Phase 3
12 A Phase III Trial of Induction Paclitaxel and Carboplatin Followed By Standard Radiotherapy (64 Gy/7 Weeks) vs. Hyperfractionated Accelerated Radiotherapy (HART 57.6 Gy/2.5 Weeks) For Patients With Unresectable Stage IIIA and IIIB Non-Small Cell Lung Cancer Completed NCT00003235 Phase 3 carboplatin;paclitaxel
13 Concurrent Carboplatin, Paclitaxel, and Radiation Therapy Versus Induction Carboplatin and Paclitaxel Followed by Concurrent Carboplatin, Paclitaxel and Radiation Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase III Trial Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
14 A Phase III Comparison Between Concurrent Chemotherapy Plus Radiotherapy and Concurrent Chemotherapy Plus Radiotherapy Followed by Surgical Resection for Stage IIIA (N2) Non-Small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
15 Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Non-small Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase III Trial Active, not recruiting NCT00030771 Phase 3 Chemotherapy
16 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
17 A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
18 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
19 Double Blind Randomized Phase III Study of Maintenance Pazopanib Versus Placebo in NSCLC Patients Non Progressive After First Line Chemotherapy. MAPPING, an EORTC Lung Group Study. Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
20 Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
21 A Randomized Phase III Trial of Carboplatin, Paclitaxel and Thoracic Radiotherapy, With or Without Thalidomide, in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
22 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
23 A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
24 A Randomized, Phase III Multicenter Trial Of Gemcitabine In Combination With Carboplatin Or Paclitaxel Plus Carboplatin In Patients With Metastatic (Stage IIIB, IV) Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
25 A Phase III Randomized, Open-Label Comparative Study of Induction Chemotherapy Followed by Thoracic Radiation Therapy With Supplemental Oxygen, With or Without Concurrent RSR13 (Efaproxiral), in Patients With Locally Advanced Unresectable (Stage IIIA/IIIB) Non-Small Cell Lung Cancer Withdrawn NCT00055887 Phase 3 carboplatin;cisplatin;efaproxiral;gemcitabine hydrochloride;paclitaxel;vinorelbine ditartrate
26 Phase II Study Of Gemcitabine And Docetaxel In Patients With Inoperable Stage IIIB Or IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00075517 Phase 2 docetaxel;gemcitabine hydrochloride
27 First Line Treatment of Stage IIIb/IV Non Small Cell (NSC) Lung Cancer With a Bimonthly Administration of a Combination of Cisplatin-Gemcitabine Unknown status NCT00006116 Phase 2 cisplatin;gemcitabine hydrochloride
28 A Phase II Study of Non-Small Cell Cancer of the Lung Utilizing Low-Dose Weekly Therapy of Taxotere and Carboplatin Unknown status NCT00003562 Phase 2 carboplatin;docetaxel
29 A Phase II Trial of Neoadjuvant Gefitinib Therapy Based on Mutation Study in Biopsy- Proven Stage IIIA N2 Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
30 A Phase II Multicenter Study Of Lometrexol Sodium And Folic Acid In Subjects With Previously Treated Stage IIIB or IV Non-Small Cell Lung Cancer Unknown status NCT00033722 Phase 2 lometrexol
31 A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
32 Paclitaxel/Carboplatin Combined With Intermittent Gefitinib in Patients With Untreated Advanced Non-small Cell Lung Cancer: A Phase â…¡a Trial Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
33 A Phase II, Open Label Study of Gefitinib (IRESSA) in Treatment-Naïve Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer and Somatic Activating Mutations in the Epidermal Growth Factor Receptor Completed NCT00411047 Phase 2 gefitinib
34 Vinorelbine Plus Bevacizumab as First Line Therapy in Patients ≥ 70 Years of Age With Stage IIIB/IV Non-Squamous, Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
35 Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer Completed NCT00036920 Phase 2 canfosfamide hydrochloride
36 Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cell Lung Cancer Patients Age Seventy and Older, or With Performance Status 2 Completed NCT00026156 Phase 2 docetaxel;vinorelbine tartrate
37 Phase II Trial Of Karenitecin (IND 57250) In Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
38 A Randomized Phase II Trial of Paclitaxel-Carboplatin or Gemicitabine-Cisplatin in ECOG Performance Status 2 Non-Small Cell Lung Cancer Patients Completed NCT00006004 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
39 Randomized Phase II Trial of Carboplatin/Gemcitabine Followed By Paclitaxel or Cisplatin/Vinorelbine Followed by Docetaxel in Advanced Non-Small Cell Lung Cancer Completed NCT00003587 Phase 2 carboplatin;cisplatin;docetaxel;gemcitabine;paclitaxel;vinorelbine
40 A Phase II Trial of Induction Paclitaxel Plus Carboplatin Followed by Thoracic Radiation Therapy With Concurrent Weekly Low-Dose Paclitaxel and Twice Weekly Amifostine for Patients With Unresectable Locally Advanced or Partially Resected Non-Small Cell Lung Cancer Completed NCT00003089 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
41 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Operable Stage I/II Non-Small Cell Lung Cancer Completed NCT00551369 Phase 2
42 Bevacizumab and Erlotinib First-Line Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (Stage IIIB/IV) Followed by Platinum-Based Chemotherapy at Disease Progression. A Multicenter Phase II Trial Completed NCT00354549 Phase 2 bevacizumab + erlotinib hydrochloride;gemcitabine hydrochloride + cisplatin or carboplatin
43 A Phase II Study of Taxotere and Gemcitabine for Stages III-B and IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
44 Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of a Chemotherapy Regimen With Bi-Weekly Docetaxel in the Treatment of Metastatic or Locally Advanced Non-Small Cell Lung Cancer in Patients Over the Age of 70 Completed NCT00227708 Phase 2 docetaxel
45 A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients With Medically Inoperable Stage I/II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
46 A Phase II Study of Temozolomide and Radiation Therapy in Patients With Brain Metastasis From Non-small Cell Lung Cancer (NSCLC) Completed NCT00080938 Phase 2 Temozolomide
47 A Randomized Phase II Study Of Triapine® Alone Versus Triapine and Gemcitabine As Second-Line Treatment Of Advanced Non-Small-Cell-Lung Cancer In Patients Who Had Prior Gemcitabine With Evaluation Of The Effect Of Triapine® On Gemcitabine Pharmacokinetics and Cellular Uptake In Peripheral Mononuclear Cells Completed NCT00077415 Phase 2 gemcitabine hydrochloride;triapine
48 A Phase II Randomized Study Of Dose-Dense Docetaxel And Cisplatin Every Two Weeks With Pegfilgrastim And Darbepoetin Alfa With And Without The Chemoprotector BNP7787 In Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00077311 Phase 2 cisplatin;docetaxel;BNP7787
49 A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer Completed NCT00023673 Phase 1, Phase 2 carboplatin;paclitaxel
50 Alternating Phase I/II Trials of Twice-Weekly Infusion Gemcitabine (2'2'-Difluoro-2'-Deoxycytidine) and Concurrent Thoracic Radiation Alone - Or Following 2 Cycles of Cisplatin/Gemcitabine Induction Chemotherapy for the Treatment of Stage IIIA/IIIB Non Small Cell Lung Cancer (NSCLC) Completed NCT00003202 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride

Search NIH Clinical Center for Lung Large Cell Carcinoma

Sources

Genetic Tests for Lung Large Cell Carcinoma

About this section
Sources

Anatomical Context for Lung Large Cell Carcinoma

About this section

MalaCards organs/tissues related to Lung Large Cell Carcinoma:

40
Lung, Lymph Node, Thyroid, Endothelial, Bone Marrow, Spinal Cord
Sources

Publications for Lung Large Cell Carcinoma

About this section

Articles related to Lung Large Cell Carcinoma:

(show top 50) (show all 223)
# Title Authors PMID Year
1
Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. 61
33568870 2021
2
Anticancer Activity of Novel Plant Extracts and Compounds from Adenosma bracteosum (Bonati) in Human Lung and Liver Cancer Cells. 61
32599892 2020
3
Secretagogin, a marker for neuroendocrine cells, is more sensitive and specific in large cell neuroendocrine carcinoma compared with the markers CD56, CgA, Syn and Napsin A. 61
32194720 2020
4
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers. 61
33584678 2020
5
A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis. 61
32944497 2020
6
Cancer-associated Retinopathy with Neuroendocrine Combined Large-cell Lung Carcinoma and Adenocarcinoma. 61
31327819 2019
7
Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. 61
31531741 2019
8
Unraveling the large cell lung carcinoma-specific miRNA profile and the downstream regulation network. 61
31555828 2019
9
Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. 61
31360195 2019
10
Doxycycline inhibits electric field-induced migration of non-small cell lung cancer (NSCLC) cells. 61
31147570 2019
11
Outcomes comparison between neoadjuvant chemotherapy and adjuvant chemotherapy in stage IIIA non-small cell lung cancer patients. 61
31179087 2019
12
Connexin43 Suppresses Lung Cancer Stem Cells. 61
30717421 2019
13
Clinical characteristics and prognosis of basaloid squamous cell carcinoma of the lung: a population-based analysis. 61
31106047 2019
14
Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT. 61
31496800 2019
15
Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma. 61
30166013 2018
16
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 61
29988660 2018
17
Anticancer Gold(III) Peptidomimetics: From Synthesis to in vitro and ex vivo Biological Evaluations. 61
29570944 2018
18
Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria. 61
29525405 2018
19
Stereochemical Structure Activity Relationship Studies (S-SAR) of Tetrahydrolipstatin. 61
29541373 2018
20
The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro. 61
29230631 2018
21
Unravelling the Long Non-Coding RNA Profile of Undifferentiated Large Cell Lung Carcinoma. 61
29657301 2018
22
Laparoscopic Splenectomy for Splenic Metastasis from Primary Lung Carcinoma. 61
29732229 2018
23
Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer. 61
28176646 2018
24
Personalized siRNA-Nanoparticle Systemic Therapy using Metastatic Lymph Node Specimens Obtained with EBUS-TBNA in Lung Cancer. 61
28993508 2018
25
Correlation between STK33 and the pathology and prognosis of lung cancer. 61
29085482 2017
26
TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. 61
28789440 2017
27
Comparison of human lung cancer cell radiosensitivity after irradiations with therapeutic protons and carbon ions. 61
27633574 2017
28
[Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma]. 61
28468033 2017
29
A global view of regulatory networks in lung cancer: An approach to understand homogeneity and heterogeneity. 61
27894849 2017
30
[Precision medical treatment of non-adenocarcinoma NSCLC patients with EGFR mutation]. 61
28219201 2017
31
Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations. 61
28790845 2017
32
Immune-associated proteins with potential in vivo anti-tumor activities are upregulated in lung cancer cells treated with umbelliprenin: A proteomic approach. 61
28105238 2016
33
[Two Cases of Small Intestinal Metastasis of Lung Cancer]. 61
28133150 2016
34
Differentiating brain metastases from different pathological types of lung cancers using texture analysis of T1 postcontrast MR. 61
26621795 2016
35
Variations of chromosome 2 gene expressions among patients with lung cancer or non-cancer. 61
27301951 2016
36
Discovery of 'click' 1,2,3-triazolium salts as potential anticancer drugs. 61
27679544 2016
37
Blood-borne miRNA profile-based diagnostic classifier for lung adenocarcinoma. 61
27507195 2016
38
Treatment of lung large cell neuroendocrine carcinoma. 61
26943800 2016
39
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. 61
26942444 2016
40
Four Cu(ii) complexes based on antitumor chelators: synthesis, structure, DNA binding/damage, HSA interaction and enhanced cytotoxicity. 61
27071545 2016
41
[Large-cell lung carcinoma by the 2015 WHO classification: a clinicopathologic analysis of 93 cases]. 61
27033385 2016
42
Brachial metastatic plexopathy as the inaugural manifestation of lung cancer: multimodality imaging. 61
30460024 2016
43
[A clinical review of 3 cases of children with bronchial tumor]. 61
26696483 2015
44
Digging Deep for New Compounds from the Compass Plant, Silphium laciniatum. 61
26287548 2015
45
Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology. 61
25793929 2015
46
Mediastinal small cell cancer associated with Lambert-Eaton myasthenic syndrome: A case report. 61
26170921 2015
47
Lung transthoracic ultrasound elastography imaging and guided biopsies of subpleural cancer: a preliminary report. 61
24951615 2015
48
Large cell lung carcinoma with rhabdoid phenotype: Report of a rare entity presenting with chest wall involvement. 61
26458655 2015
49
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. 61
25937073 2015
50
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. 61
25638031 2015
Sources

Variations for Lung Large Cell Carcinoma

About this section

Cosmic variations for Lung Large Cell Carcinoma:

9 (show top 50) (show all 2927)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87291734 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 15
2 COSM102042323 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8009A>G p.? 16:72958974-72958974 15
3 COSM102040476 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.-23-8037G>T p.? 16:72959002-72959002 15
4 COSM149314749 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 15
5 COSM87290218 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1144G>T p.G382C 16:72959002-72959002 15
6 COSM149318860 ZFHX3 lung,NS,carcinoma,undifferentiated carcinoma c.1172A>G p.Q391R 16:72958974-72958974 15
7 COSM126973051 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.770C>T p.P257L 11:102229729-102229729 15
8 COSM145028029 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1154C>T p.P385L 11:102229729-102229729 15
9 COSM128452039 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1142C>T p.P381L 11:102229729-102229729 15
10 COSM85237448 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1304C>T p.P435L 11:102229729-102229729 15
11 COSM143041512 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1316C>T p.P439L 11:102229729-102229729 15
12 COSM127997731 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1256C>T p.P419L 11:102229729-102229729 15
13 COSM133274224 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1268C>T p.P423L 11:102229729-102229729 15
14 COSM90948266 YAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1202C>T p.P401L 11:102229729-102229729 15
15 COSM108017622 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 15
16 COSM95166535 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 15
17 COSM105839764 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1009A>C p.I337L 22:41653558-41653558 15
18 COSM97230831 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 15
19 COSM103711109 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1036A>C p.I346L 22:41653558-41653558 15
20 COSM106337415 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 22:41653558-41653558 15
21 COSM85312404 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 19:43546970-43546970 15
22 COSM134125623 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1114A>G p.M372V 19:43546970-43546970 15
23 COSM100781761 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.724A>T p.K242* 11:32392044-32392044 15
24 COSM113475703 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
25 COSM111529696 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
26 COSM113484991 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
27 COSM147414475 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
28 COSM149739953 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
29 COSM148593279 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
30 COSM91372655 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
31 COSM148580942 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
32 COSM130518653 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.673A>T p.K225* 11:32392044-32392044 15
33 COSM149728755 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.437G>A p.W146* 11:32434909-32434909 15
34 COSM111539040 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 15
35 COSM91383011 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1360A>T p.K454* 11:32392044-32392044 15
36 COSM147426277 WT1 lung,NS,carcinoma,undifferentiated carcinoma c.1309A>T p.K437* 11:32392044-32392044 15
37 COSM124478343 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.422G>C p.G141A 5:138088927-138088927 15
38 COSM104050903 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 5:138088927-138088927 15
39 COSM105123686 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 15
40 COSM87652733 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 12:48966259-48966259 15
41 COSM102763785 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.*288A>C p.? 12:48966259-48966259 15
42 COSM98261314 WNK3 lung,NS,carcinoma,large cell carcinoma c.4458G>T p.L1486F 23:54236967-54236967 15
43 COSM144807452 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 15
44 COSM98245214 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 15
45 COSM89575026 WNK3 lung,NS,carcinoma,large cell carcinoma c.4599G>T p.L1533F 23:54236967-54236967 15
46 COSM99767946 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 15
47 COSM84601598 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 12:6856877-6856877 15
48 COSM121848752 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 15
49 COSM88410243 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4:143197868-143197868 15
50 COSM87541563 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64= 17:60301699-60301699 15
Sources

Expression for Lung Large Cell Carcinoma

About this section
Search GEO for disease gene expression data for Lung Large Cell Carcinoma.
Sources

Pathways for Lung Large Cell Carcinoma

About this section

Pathways related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.56 ROS1 NTRK3 MYO18B MTOR FGFR1 EPHA5
2
Akt Signaling 63
Show member pathways
 13.17 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
3
p70S6K Signaling 63
Show member pathways
 12.73 NTRK3 MTOR FGFR1 EPHA5 EPHA3 DDR2
4
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 12.53 ROS1 NTRK3 MYO18B FGFR1 EPHA5 EPHA3
5
G-protein signaling RAC1 in cellular process 23
Show member pathways
 11.8 ROS1 NTRK3 MTOR FGFR1 EPHA5 EPHA3
6
Guidance Cues and Growth Cone Motility 63
11.63 NTRK3 EPHA5 EPHA3 ABL1
7
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.53 SYP NCAM1 FGFR1
8
Central carbon metabolism in cancer 36
11.43 NTRK3 MTOR FGFR1
9
Tyrosine Kinases / Adaptors 4
11.27 ROS1 FGFR1 EPHA5 EPHA3 DDR2 ABL1
10
G-protein signaling_Rap2B regulation pathway 23
10.7 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
Sources

GO Terms for Lung Large Cell Carcinoma

About this section

Cellular components related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.5 SYP STK33 ROS1 NME1 EPHA5 CHGA
2 receptor complex GO:0043235 9.1 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2

Biological processes related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
2 axon guidance GO:0007411 9.81 NKX2-1 NCAM1 EPHA5 EPHA3
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
4 protein autophosphorylation GO:0046777 9.77 STK33 MTOR FGFR1 DDR2 ABL1
5 peptidyl-tyrosine phosphorylation GO:0018108 9.76 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
6 neuron migration GO:0001764 9.75 NTRK3 NKX2-1 FGFR1
7 regulation of GTPase activity GO:0043087 9.73 MTOR EPHA5 EPHA3
8 positive regulation of neuron projection development GO:0010976 9.73 NTRK3 NME1 MTOR EPHA3
9 positive regulation of kinase activity GO:0033674 9.73 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
10 protein phosphorylation GO:0006468 9.73 TTN STK33 ROS1 NTRK3 MTOR FGFR1
11 ephrin receptor signaling pathway GO:0048013 9.72 NTRK3 EPHA5 EPHA3
12 regulation of actin cytoskeleton organization GO:0032956 9.71 MTOR EPHA5 EPHA3 ABL1
13 hippocampus development GO:0021766 9.67 NME1 NKX2-1 EPHA5
14 positive regulation of phospholipase C activity GO:0010863 9.57 NTRK3 FGFR1
15 signal transduction in response to DNA damage GO:0042770 9.54 STK33 ABL1
16 cardiac muscle cell development GO:0055013 9.52 MTOR ALPK3
17 cardiac muscle fiber development GO:0048739 9.48 TTN MYO18B
18 phosphorylation GO:0016310 9.44 TTN STK33 ROS1 NTRK3 NME1 MTOR

Molecular functions related to Lung Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.22 TTN STK33 ROS1 NTRK3 NME1 MTOR
2 nucleotide binding GO:0000166 10.18 TTN STK33 ROS1 NTRK3 NME1 MYO18B
3 ATP binding GO:0005524 10.1 TTN STK33 ROS1 NTRK3 NME1 MYO18B
4 protein serine/threonine kinase activity GO:0004674 9.85 TTN STK33 MTOR ANKK1 ALPK3
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.8 ROS1 NTRK3 FGFR1 EPHA5 EPHA3 DDR2
6 protein tyrosine kinase activity GO:0004713 9.76 TTN ROS1 NTRK3 FGFR1 EPHA5 EPHA3
7 protein kinase activity GO:0004672 9.7 TTN STK33 ROS1 NTRK3 MTOR FGFR1
8 GPI-linked ephrin receptor activity GO:0005004 9.61 NTRK3 EPHA5 EPHA3
9 ephrin receptor activity GO:0005003 9.48 EPHA5 EPHA3
10 kinase activity GO:0016301 9.44 TTN STK33 ROS1 NTRK3 NME1 MTOR
Sources

Sources for Lung Large Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....